LGM
IMMU

Logos Global Management’s Immunomedics Inc IMMU Stock Holding History

Logos Global Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-276,635
Closed -$3.73M – 73
2020
Q1 		$3.73M Buy
+276,635
New +$4.65M 1.42% 30

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Logos Global Management's IMMU Position: Q2 2020 in Review

Logos Global Management sold out of Immunomedics Inc (IMMU) in Q2 2020, closing a stake of 276,635 shares — an estimated $3.73M sold.

Logos Global Management first reported a position in IMMU in Q1 2020 and held it in 1 quarter. The position peaked at $3.73M in Q1 2020. 313 funds tracked by Wall St. Rank hold IMMU as of Q2 2020.

  • Logos Global Management reported no remaining Immunomedics Inc position as of Q2 2020 after selling out during the quarter.
  • Logos Global Management sold 276,635 Immunomedics Inc shares in Q2 2020, an estimated $3.73M.
  • Logos Global Management first reported a position in Immunomedics Inc in Q1 2020 and held it in 1 quarter.
  • Logos Global Management's Immunomedics Inc position peaked at $3.73M in Q1 2020.
  • 313 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2020.

Based on Logos Global Management's 13F filing for Q2 2020, filed 14 Aug 2020.